Goldman Sachs Group Inc Anavex Life Sciences Corp. Put Options Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$4.11 - $7.04 $646,914 - $1.11 Million	157,400 New	157,400 $894,000
Q1 2023 May 14, 2024	BUY	$8.32 - $11.75 $91,520 - $129,250	11,000 Added 4.55%	252,500 $2.16 Million
Q1 2023 May 11, 2023	BUY	$8.32 - $11.75 $91,520 - $129,250	11,000 Added 4.55%	252,500 $2.16 Million
Q4 2022 May 14, 2024	BUY	$7.65 - $14.43 $1.85 Million - $3.48 Million	241,500 New	241,500 $2.24 Million
Q4 2022 Feb 13, 2023	BUY	$7.65 - $14.43 $1.85 Million - $3.48 Million	241,500 New	241,500 $2.24 Million

155

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $847M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.